<SEC-DOCUMENT>0001144204-14-011794.txt : 20140226
<SEC-HEADER>0001144204-14-011794.hdr.sgml : 20140226
<ACCEPTANCE-DATETIME>20140226172234
ACCESSION NUMBER:		0001144204-14-011794
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140226
FILED AS OF DATE:		20140226
DATE AS OF CHANGE:		20140226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Dehaier Medical Systems Ltd
		CENTRAL INDEX KEY:			0001474627
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34661
		FILM NUMBER:		14645828

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
		BUSINESS PHONE:		(8610) 5166-0080

	MAIL ADDRESS:	
		STREET 1:		SUITE 501, JIUZHOU PLAZA
		STREET 2:		83 FUXING ROAD,
		CITY:			HAIDIAN DISTRICT, BEIJING
		STATE:			F4
		ZIP:			100856
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v369870_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>U.S. SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the month of February 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number: 001-34661</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Dehaier Medical Systems Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Dehaier Medical Systems Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Room 501, 83 Fuxing Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Haidian District, Beijing 100856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">People&rsquo;s Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Cautionary
Note Regarding Forward-Looking Statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Report, including the exhibits included
herein, may contain forward-looking statements.&nbsp;&nbsp;We have based these forward-looking statements on our current expectations
and projections about future events.&nbsp;&nbsp;Our actual results may differ materially from those discussed herein, or implied
by, these forward-looking statements.&nbsp;&nbsp;Forward-looking statements are generally identified by words such as &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;project&rdquo;
and other similar expressions. In addition, any statements that refer to expectations or other characterizations of future events
or circumstances are forward-looking statements. Forward-looking statements included in this Report are subject to significant
risks and uncertainties,&nbsp;including but limited to:&nbsp;risks and uncertainties&nbsp;associated with the integration of the
assets and operations we have acquired and may acquire in the future; our possible inability to raise or generate additional funds
that will be necessary to continue and expand our operations; our potential lack of revenue growth and other factors&nbsp;detailed
in the Company&rsquo;s filings with the Securities and Exchange Commission. These forward-looking statements involve certain risks
and uncertainties that are subject to change based on various factors (many of which are beyond the Company&rsquo;s control). The
Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">On February 26,
2014, Dehaier Medical Systems Limited (the &ldquo;Registrant&rdquo;) issued a press release announcing the closing of a previously
announced securities purchase agreement (the &ldquo;Securities Purchase Agreement&rdquo;) with certain institutional investors
for the sale of 734,700 common shares in a registered offering at the price of $9.12 per common share. A copy of the press release
is attached as Exhibit&nbsp;99.1 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Gross proceeds
from the offering were approximately $6.7 million. After payment of expenses, the Company received approximately $6.1 million in
net proceeds. In addition, warrants to purchase 220,410 common shares in the aggregate were issued to the investors. If fully exercised,
the Company would receive aggregate gross proceeds from the warrants of approximately $2.6 million. The company intends to use
the net proceeds from this offering for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">99.1</TD>
    <TD STYLE="font-size: 10pt">Press Release dated February 26, 2014.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 48.95pt">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>DEHAIER MEDICAL SYSTEMS LIMITED</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 62%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">February 26, 2014</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">/s/ Ping Chen</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Ping Chen</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Chief Executive Officer</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>(Principal Executive Officer) and</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Duly Authorized Officer</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>99.1</TD>
    <TD>Press Release dated February 26, 2014.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v369870_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Exhibit 99.1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 80px; width: 226px">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dehaier Announces Closing of $6.7 Million
Registered Direct Offering of Common Shares and Warrants&#8232;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 26.8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 26.8pt"><B>BEIJING, February 26, 2014 - Dehaier
Medical Systems Ltd.</B> (NASDAQ: DHRM) (&ldquo;Dehaier&rdquo; or the &ldquo;Company&rdquo;), an emerging leader in the development,
assembly, marketing and sale of medical devices and homecare medical products in China, today announced the closing of a previously
announced securities purchase agreement (the &ldquo;Securities Purchase Agreement&rdquo;) with certain institutional investors
for the sale of 734,700 common shares in a registered offering at the price of $9.12 per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 26.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gross proceeds from the offering were approximately $6.7 million.
After payment of expenses, the Company received approximately $6.1 million in net proceeds. In addition, warrants to purchase 220,410
common shares in the aggregate were issued to the investors. If fully exercised, the Company would receive aggregate gross proceeds
from the warrants of approximately $2.6 million. The company intends to use the net proceeds from this offering for working capital
and other general corporate purposes. FT Global Capital, Inc. served as the placement agent for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 26.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28pt">A registration statement relating to these
securities has been filed with the Securities and Exchange Commission and has become effective. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This news release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives,
goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are
other than statements of historical facts, including in particular any implications regarding the implications. These statements
are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, fulfillment of
bids and contracts, changes in technology, economic conditions, the impact of competition and pricing, government regulation,
and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking
statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims
any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contact Us</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dehaier Medical Systems Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28pt; text-align: justify; text-indent: -28pt">Surie Liu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+86 10-5166-0080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><U>lius@dehaier.com.cn</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dehaier Medical Systems Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tina He</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+86 10-5166-0080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><U>hexw@dehaier.com.cn</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!0`.(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`**@FG6(>K'HH[^WZ4^*59HED0Y5AD$4"\B2BBB@84444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!12"HY9?*4$(S9[#']3
M0!)5:[E,-N9.@'WFZ[1Z_AUK(U3Q#-:`K'%;1L>AGG&3]$3)-<]>^(=88?-.
MT<9Z^7IVQ?\`OJ9A_*M84I2,Y5$C9OK\IDN64Y.0O+*1R0!W*_>'JI-0Z;X@
M^S7VR<H+:5U5RIRL4C?=8'O')V/9N/IR5OJOG,UM/([R1KD,LD9DDC7G("$@
M21]5]0"*1[@*61T24893'']V5&&YT7_98?O$]&!%='L.AA[7JCURBN0\.>)A
M)8M933+->08"2,<"6+&5E/MCK[@BMVVU$-M60G)QSCGGID>I]/2N64'%V9T1
MFF:5%(&##(.1[5Q.I?$,6_C./P]96:SR%@KS--L"MU(Y'/'Z\5!9W%%>>ZW\
M4ET>V61]'FWNV$#W$1!_[Y)/Z5/IOQ):\L89YM&G#2#<!'/$1CMC+`_F*5QV
M.ZHKE?%OC5?"<%I-)8-<)<<%1,JNAX_AY)JOJWC\6BV']E:5=ZDUX@EPBE!&
M#T!)!P>N1VIA8[*BN5?QI-;)&;O0=0A9SC#20@%O0$OS6L=:BAT)M5OXI+.)
M$+NDI7<H'T)'/;GO0(U:*\\\/_%";7)I670+\VL?!DME,Q#=@<`8_.M>\^(%
MGIULUQ>Z7K-O`O!DEM"J@YQUS2N%F=716)X>\4V7B>RFN].CN!!&VS=*FW<<
M9..:Y_3OBG:ZLUP+'2;Z46Z[Y3NC4(N>I)84P.[HKD;;QXUY$7M=%NID!P62
MX@(SZ??K3TGQ!/JETT3Z3=VR!<^:[QLH]OE8F@=C;HK!U+QAI.F1:@9)VEDT
M\!KB*)260$@#K@=_6LA?B.E[8?:=(T#6[X,<(5MB$;GGYAGTH$=K17)P^.7:
M!&G\,^(8Y"/F5;(L`?KGGZUTT$WGV\4H5TWJ'VN,,,]B.QH`GHHHH`****`"
MJ]T@:!MVT@#^(#'\JGI"-RX-"$<EJ*.T;+"[X[B'>WYB,+^IKC[Y+6WD/GM%
M$_4^8\$;?D?,>NN\:QPQV]I`2^)9M\N9&_U4:EV[]#@#\:\\.G(C*S0J&B3>
MR*!RP7>1_P!]2(OX5Z6&5U<XZSL[$5S<+-*IT^027,)\Q#"TDA4CO@(!3;O4
MQY"F-3%(.5CY!3YL[<?[+\CV;%;'A#68/#6OWL3VC3H0(FDBY==OWB%[C.>G
M2L^]UBTU7Q-=ZK%";=F8;,C)3'&[;WD/8=NN>*Z4WSVMH86TO<U]'1K&',BI
M]H9OG1C\JMRXA![(N3(_X"NDL-0W]2[$X//#MO\`NCV>3[W^RF.E<E:R>?LV
MI'LP52-FRFT<D%O^>8/S.Q^\1BNU\)::;ADU*<N8EW-;F08:5F^],P[$]`.R
MUQ5TEJSHI:Z(Z:TA>&(>:V7/4+PJ^P'H*\@\1F6S^-$.V03/-L4>:N0@9<8'
M'OU]Z]IKRWQAX*\0ZOX^35-)\N")%C"7+R`;"O?;U/Y5P,[$</8P6^G:9';W
M2:=+(E\ER9I"Z[D48,7W.A^M374%KJ4'D6\>FVQEU!KD3H7;;&W`C^YT%;R^
M$/%&D7=[97MM/K>FWL/EN8YP,'J&&X\$$=^*9H.B>+-,UVVFGTO4I["U^6"U
M:\50H_A#$<$#.>E%B[FK\:'\C1-(C58RWFG$F/F7`'0]OIWXKD?%UU-=>*M*
M6YCO9%-K;K(K'#7'J1@]\G\:]!^*'AG5?$UGID.FVPD>.1C)F15"`@=R>>E0
MZQ\-+[5M6TS4(]3CM9+.WAC($98AD[@]#0),\LU*&V?1I+J"&7/VKRU<1E4C
MX)VDECST_*O9_"L=CJ'PUT]-6MA]DAMPTBW`^4A1G=]*X[Q5X&UJYF&GZ?'<
M7(><2R3-!##"QQ][(.21D@\5V&I>#=0O?!ECH%OJR6L<,*Q7#"'=YV`.!SD#
M(_&@&SS2[\0:CJ^GZW#HBQ6&@6P\PPQQA>-X"\]=Q//7U%4+;4M7L/"UG<3>
M5>Z3)>-F"=-X$B@<'ZCI^->B:IX,F\/_``_GT31[.;4;F^8>=.F%P00<D9Z<
M>]6_#GP_=?A]+H>N;0\\IF_=G)B/&.>F1C]<4!<Z3P[-IMQX8@GT:&.&REC+
M+'&``A[CCOG->0?#6Q349M:MY+#^T%:%#]F,OEA\/W;MZ\UZ1X,\&W_A**ZM
MFU47=E)DI!Y6W:WKG)QP.E<?X+\*^+O#EUJ$D6F1J]Q%Y:N]RB[.<@C@]*`.
M;\8BT7Q396<&E6NG"U54FA$ZLI^;/S.![]Z]C\-%EWF+0+;3;:5!();>6-Q)
MZ<*/3/-<AI7@O4M-2^\_0K>^EOE*S2W.H`L03D@$)QD]^O2MWP5I&LZ"QLI[
M<1Z><LH>\\TQ?[*@*.#GO0#.5\<Z?)IE_P")IQ<64BZA;QGR?.VS1@,#G9CD
M<=:UO`/A^#6_`.EO/=7T!B:8#[-<M%NS(>H'6J/B[PYJ9U+6K@V=UJ%UJ<*Q
M6[6T(\J%`PX8DY!POIW_`"ZSP7IUUX7\#6MMJ$#F>+<[Q0CS&&YB<`#KUH#H
M<1X,AOO$OBVXGLM4U&VTG3Y%)BENWD>0]@<^N.?R%>PXKSWX6>'=3T4:K/J5
MJUL+IU,2N1N(&[MVZCK7H5,EBT444`%%%%`!1110!QOBV!KS55AVY46RQ?\`
M?Z95/_CJ'\ZYQ8`\IF8?*[K*?H6DF/Z1I7=7T!ENY)MISN&WCKL!Q_X\WZ5G
M2:4AA,2*,$%!_P!\"(?^S&NNE5Y8V.><+NYYGIMK,<[U+N_[TQ.I)'^UM^]W
M^\AS[5IM8VFHQ^9<HK@?+YS/M*_28#!^DB@^]=I?^`X1$1I;HD>=WV6XRT6?
M53]Z,^ZG\*R'TZXLK@&\AE@D''F3%B#["XCYQ[2*:Z/K$9[&/LFMROI7AE$N
M83<2R26;,"\,B!&E"XVKO!*,@ZX!&>^:])@=9(@R`A1Q@C&/PKG-/M_+1=@Q
MYGH%Q)^*_(_Y`UTD,8CB51Q@=!GBN*M-R=V=-./*2YKA/$WB/5K?7M4MK"ZC
MM[?3M,-VQ,(<N^>%R?7^E=W6)?\`A'2-3O9KJ[MF>6<*LV)742!>@*@X(K$U
M1F7'C-]-T?0I+NV62]U1%PH<HBG:"23@D`9';O3;GQC-)X#O];BM&L[B`,B)
M+\PW`X!Y`R,GVK<U#P_IVIFT-Q!A[//D/&YC:/(P<$$>@I)O#NFW&C_V9+;[
M[0L&*%V)8AMV2<Y)S1J,S="\3SWMW<Z?J%KY-U96T<\LBR`J^Y<^V#[=/>J^
ME^.DU'7K/3%MHS]JC>198;@2A0O7=\H';'!(K=70]/2YOIQ;*9+Y`EP22?,4
M#:!CTP:K:=X2TC2;V.ZLK4I-#&8XRTKML4]@"<`4:@9=OXP\JV\1ZA<B22TT
MNX,2*JJ"Q'!P?J1UJQX>\7OKE]);RZ>]L%MUG$H<NG/\))4<C/N*T(_#6E1Z
M;>6`M`;6\D:6="S'>S$9.<Y[5)9:%96,<B0))B1!&QDE9SM_N@D\#GM1J!D^
M&/%5[XE$=Q'HS0:>Y<?:6N%/W3@`+C)SSS7274XMK2:9ND:%S^`S5?2],M-'
ML(K&PB\FVBR$0$G&3D]?<FIKNVCO+2:VG7='*A1USC((P:!'E>G_`!*UO^Q+
MW[;%&=2DB6>QQ'A3'@[F/L`I/Z5T<'CB:ST#07OX5GU#5$+X!\M%`YR3@D<$
M=!73?V!IPT?^ROLR_8_),`0$YV>F<Y[U!<>%]+N4LE:W9#8KLMFCE9&C&,8#
M`@]*0[F4GCKS=*TV==,F%YJ%T;6*V=PN"#RQ;'3\,UF)XTU$>%]=U.Y`1K>]
M-M;+$JG;R%ZD8/)[UU-QX7TJZM+:VEMB4M7WPMYC!T8G).[.<GOS48\(Z,ND
M#31:'[)YWVCR_,;E\YR3G/6GJ&A#?>(Y[34['2K6Q:\OI[8W#`RB)54>IP>2
M>/3WINN^+!HJQAH(?-:W,[1RW(4C'\(`#$GWZ>]7M1\-Z;JUW%<WMOOGC3RP
MZNR$H3G:<$9'L:9J7A32=7N!/=VN91"8-Z2,A,?]TX(R.:!&-+XNN;P^%VL8
M_)&KREI(Y!N(C`R<?XUV58<_A'2;F.Q1[>1/L">7;&.9T,:X`/(/M6O!&L$,
M<2[MJ*%&XDG@8Z]_K2`FHHHI@%%%%`!1110`F,]:9Y:`@[1D=_\`/UJ2B@`I
M,9ZTM%`%5;&))"\:["?O!<`-]1TJU24M`@HHHH&%%%%`!1110`4444`%%%%`
;!1110`4444`%%%%`!1110`4444`%%%%`'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
